Found an issue? Give us feedback

The Medical Letter o...arrow_drop_down

The Medical Letter on Drugs and Therapeutics

Article . 2023 . Peer-reviewed

Data sources: Crossref

The Medical Letter on Drugs and Therapeutics

Article . 2023

Data sources: Europe PubMed Central

Select content type to embed

All Research products

arrow_drop_down

<script type="text/javascript">
<!--
document.write('<div id="oa_widget"></div>');
document.write('<script type="text/javascript" src="https://www.openaire.eu/index.php?option=com_openaire&view=widget&format=raw&projectId=undefined&type=result"></script>');
-->
</script>

COPY SCRIPT

For further information contact us at helpdesk@openaire.eu

Capmatinib (Tabrecta) for NSCLC

descriptionPublicationkeyboard_double_arrow_right Article 17 Apr 2023Publisher:The Medical Letter, Inc.Journal:The Medical Letter on Drugs and Therapeutics, volume 65, pages e65-e66 (eissn: 1523-2859,

doi: 10.58347/tml.2023.1674d

pmid: 37039616

Capmatinib (Tabrecta) for NSCLC

- Summary
- Subjects
- Metrics

Abstract

The FDA has granted regular approval to the oral kinase inhibitor capmatinib (Tabrecta – Novartis) for treatment of metastatic non-small cell lung cancer (NSCLC) in adults whose tumors have a mutation that leads to mesenchymal-epithelial transition (MET) exon 14 skipping. MET exon 14 skipping mutations occur in 3-4% of NSCLC cases. The drug received accelerated approval for the same indication in 2020 based on initial overall response rates and duration of response.

Keywords

Lung Neoplasms, Triazines, Carcinoma, Non-Small-Cell Lung, Imidazoles, Humans

Impact byBIP!

	citations This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	0
	popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network.	Average
	influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically).	Average
	impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network.	Average